ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Two Chinese firms get warning letters

by Jean-François Tremblay
July 11, 2016 | APPEARED IN VOLUME 94, ISSUE 28

The U.S. Food & Drug Administration has sent warning letters to two Chinese pharmaceutical chemical producers. The agency says Shanghai Desano Chemical Pharmaceutical failed to fully investigate evidence of production deviations that were revealed during analytical testing. The company also conducted “unofficial” testing and kept the data in a folder called “Test.” At Chongqing Lummy Pharmaceutical, the agency found that company analysts had falsified data generated by gas chromatographs and HPLCs by setting back their clocks. FDA also discovered that Lummy operators did not make entries in batch manufacturing records at the time operations were performed but rather completed batch records in groups.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment